222 related articles for article (PubMed ID: 22676443)
1. Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.
Kwatra D; Budda B; Vadlapudi AD; Vadlapatla RK; Pal D; Mitra AK
Mol Pharm; 2012 Jul; 9(7):1877-86. PubMed ID: 22676443
[TBL] [Abstract][Full Text] [Related]
2. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity.
Patel J; Buddha B; Dey S; Pal D; Mitra AK
Am J Ther; 2004; 11(4):262-77. PubMed ID: 15266218
[TBL] [Abstract][Full Text] [Related]
3. Construction and application of double-transfected cells expressing the human transporter P-glycoprotein and cytochrome P450 3A4.
Hu HH; Su C; Jiang Y; Yu LS; Liu Y; Tian Y; Xu SY; Zhou H; He X; Jiang HD; Zeng S
Pharmazie; 2013 Oct; 68(10):816-20. PubMed ID: 24273886
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.
Karyekar CS; Eddington ND; Garimella TS; Gubbins PO; Dowling TC
Pharmacotherapy; 2003 Apr; 23(4):436-42. PubMed ID: 12680473
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.
Kawahara I; Kato Y; Suzuki H; Achira M; Ito K; Crespi CL; Sugiyama Y
Drug Metab Dispos; 2000 Oct; 28(10):1238-43. PubMed ID: 10997946
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components.
Eagling VA; Profit L; Back DJ
Br J Clin Pharmacol; 1999 Oct; 48(4):543-52. PubMed ID: 10583025
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Utility of Canine Mdr1 Knockout Madin-Darby Canine Kidney I Cells in Permeability Screening and Efflux Substrate Determination.
Chen EC; Broccatelli F; Plise E; Chen B; Liu L; Cheong J; Zhang S; Jorski J; Gaffney K; Umemoto KK; Salphati L
Mol Pharm; 2018 Nov; 15(11):5103-5113. PubMed ID: 30222362
[TBL] [Abstract][Full Text] [Related]
8. Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.
Patel M; Sheng Y; Mandava NK; Pal D; Mitra AK
Int J Pharm; 2014 Dec; 476(1-2):99-107. PubMed ID: 25261710
[TBL] [Abstract][Full Text] [Related]
9. Creation of polarized cells coexpressing CYP3A4, NADPH cytochrome P450 reductase and MDR1/P-glycoprotein.
Brimer C; Dalton JT; Zhu Z; Schuetz J; Yasuda K; Vanin E; Relling MV; Lu Y; Schuetz EG
Pharm Res; 2000 Jul; 17(7):803-10. PubMed ID: 10990198
[TBL] [Abstract][Full Text] [Related]
10. Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa?
Tang F; Horie K; Borchardt RT
Pharm Res; 2002 Jun; 19(6):765-72. PubMed ID: 12134945
[TBL] [Abstract][Full Text] [Related]
11. Expanding the Efflux In Vitro Assay Toolbox: A CRISPR-Cas9 Edited MDCK Cell Line with Human BCRP and Completely Lacking Canine MDR1.
Wegler C; Gazit M; Issa K; Subramaniam S; Artursson P; Karlgren M
J Pharm Sci; 2021 Jan; 110(1):388-396. PubMed ID: 33007277
[TBL] [Abstract][Full Text] [Related]
12. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
13. Differences in the expression of endogenous efflux transporters in MDR1-transfected versus wildtype cell lines affect P-glycoprotein mediated drug transport.
Kuteykin-Teplyakov K; Luna-Tortós C; Ambroziak K; Löscher W
Br J Pharmacol; 2010 Jul; 160(6):1453-63. PubMed ID: 20590635
[TBL] [Abstract][Full Text] [Related]
14. Targeting SVCT for enhanced drug absorption: synthesis and in vitro evaluation of a novel vitamin C conjugated prodrug of saquinavir.
Luo S; Wang Z; Patel M; Khurana V; Zhu X; Pal D; Mitra AK
Int J Pharm; 2011 Jul; 414(1-2):77-85. PubMed ID: 21571053
[TBL] [Abstract][Full Text] [Related]
15. Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT).
Guo A; Marinaro W; Hu P; Sinko PJ
Drug Metab Dispos; 2002 Apr; 30(4):457-63. PubMed ID: 11901101
[TBL] [Abstract][Full Text] [Related]
16. Transport inhibition of digoxin using several common P-gp expressing cell lines is not necessarily reporting only on inhibitor binding to P-gp.
Lumen AA; Li L; Li J; Ahmed Z; Meng Z; Owen A; Ellens H; Hidalgo IJ; Bentz J
PLoS One; 2013; 8(8):e69394. PubMed ID: 23976943
[TBL] [Abstract][Full Text] [Related]
17. Isolation of MDCK cells with low expression of
Bokulić A; Padovan J; Stupin-Polančec D; Milić A
Acta Pharm; 2022 Jun; 72(2):275-288. PubMed ID: 36651516
[TBL] [Abstract][Full Text] [Related]
18. Transport of 5,5-diphenylbarbituric acid and its precursors and their effect on P-gp, MRP2 and CYP3A4 in Caco-2 and LS180 cells.
Fan J; Maeng HJ; Du Y; Kwan D; Pang KS
Eur J Pharm Sci; 2011 Jan; 42(1-2):19-29. PubMed ID: 20955791
[TBL] [Abstract][Full Text] [Related]
19. Involvement of organic cation transporter 1 and CYP3A4 in retrorsine-induced toxicity.
Tu M; Li L; Lei H; Ma Z; Chen Z; Sun S; Xu S; Zhou H; Zeng S; Jiang H
Toxicology; 2014 Aug; 322():34-42. PubMed ID: 24799337
[TBL] [Abstract][Full Text] [Related]
20. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
